Sarepta Therapeutics

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, January 31, 2023
SRPT, Sarepta, Sarepta Therapeutics, RSU, Employment, Financial compensation, Degenerative disease, Therapy

CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 40 individuals hired by Sarepta in January 2023.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 40 individuals hired by Sarepta in January 2023.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 41,125 shares of Sarepta's common stock, and in the aggregate 22,100 restricted stock units (“RSUs”).
  • The options have an exercise price of $124.97 per share, which is equal to the closing price of Sarepta's common stock on January 31, 2023 (the “Grant Date”).

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues

Retrieved on: 
Monday, January 9, 2023
SRPT, Sarepta Therapeutics, Therapy, Conference, Degenerative disease, Patient, RNA, PMO, Sarepta, Investment, Video game, Pharmaceutical industry, Duchenne

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2022 net product revenues as part of their presentation today at the 41st Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • - Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5 million and $843.3 million, respectively
    CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2022 net product revenues as part of their presentation today at the 41st Annual J.P. Morgan Healthcare Conference.
  • Fourth quarter 2022 net product revenues are expected to be approximately $235.5 million, a 32% increase over the same period in 2021.
  • Our expected net product revenues do not include collaboration revenues.
  • Net product revenues for the full-year 2022 are expected to be $843.3 million, a 38% increase over the same period of 2021, which is also expected to exceed Sarepta’s net product revenue guidance of $825-840 million.

Dunad Therapeutics Appoints Michael Bonney as Chair of Board of Directors

Retrieved on: 
Monday, January 9, 2023
Biotechnology, General Health, Health, Science, Research, Multiple sclerosis, Merck, Therapy, Marketing, Biogen, Sarepta Therapeutics, Interferon beta-1a, Cubist Pharmaceuticals, Bristol Myers Squibb, Chairperson, Pharmaceutical industry, Alnylam Pharmaceuticals

Dunad Therapeutics, a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Michael Bonney as Chair of its Board of Directors.

Key Points: 
  • Dunad Therapeutics, a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Michael Bonney as Chair of its Board of Directors.
  • Mr. Bonney brings more than 30 years of life sciences industry leadership experience, including serving as President and Chief Executive Officer of Cubist Pharmaceuticals and Executive Chair of Alnylam Pharmaceuticals.
  • More recently, Mr. Bonney held the position of Chief Executive Officer and Chair of Kaleido Biosciences, a company focused on developing microbiome therapies.
  • In addition to Alnylam, Mr. Bonney has served as Board Chair of Magenta Therapeutics and Director of several biopharma companies including Sarepta Therapeutics, Bristol Myers Squibb, Celgene and Syros Pharmaceuticals.

Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023
Sarepta, Software, Conference, Event, SRPT, Sarepta Therapeutics, Degenerative disease, Therapy, Q&A, Pharmaceutical industry, Online shopping, Health insurance

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023 at 1:30 p.m. E.T.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023 at 1:30 p.m. E.T.
  • / 10:30 a.m. P.T.
  • Following the presentation there will be a Q&A session starting at 1:50 p.m. E.T.
  • Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 30, 2022
Sarepta, Financial compensation, SRPT, Therapy, Sarepta Therapeutics, Degenerative disease, RSU, Employment

CAMBRIDGE, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by Sarepta in December 2022.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by Sarepta in December 2022.
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 11,325 shares of Sarepta's common stock, and in the aggregate 5,875 restricted stock units (“RSUs”).
  • The options have an exercise price of $129.58 per share, which is equal to the closing price of Sarepta's common stock on December 31, 2022 (the “Grant Date”).

Biotech Industry Leaders Join Deep Genomics Board of Directors and Scientific Advisory Board

Retrieved on: 
Friday, January 6, 2023
Health, Technology, Genetics, Artificial Intelligence, Pharmaceutical, Biotechnology, Ness, Sarepta, IPO, Organic acid, GlaxoSmithKline, Coronavirus Scientific Advisory Board (Turkey), RNA, CSO, Lead, Oncology, Oligonucleotide, Intellia Therapeutics, Art, FRSC, Drug discovery, Doctor of Philosophy, Therapy, Drug development, Pfizer, Molecular biology, Ionis Pharmaceuticals, SoftBank Group, IP Group, Investment, CFO, Sarepta Therapeutics, GSK, Genomics, Sirna Therapeutics, Patient, AstraZeneca, Biology, Atlas, Khosla Ventures, AI, DPU, Regeneron Pharmaceuticals, Moderna, Atlas Venture, PTC, Regulus Therapeutics, University, PTC Therapeutics, Pharmaceutical industry

and Mark Edbrooke, Ph.D. have joined the Scientific Advisory Board.

Key Points: 
  • and Mark Edbrooke, Ph.D. have joined the Scientific Advisory Board.
  • “These industry leaders will lend valuable support and advice to Deep Genomics as we advance our revolutionary AI drug discovery platform toward the goal of bringing programmable RNA medicines to patients,” said Brendan Frey, Ph.D., FRSC, Founder and CEO of Deep Genomics.
  • Chip has more than 20 years of experience leading innovative biotech companies and also serves as a Director of Axcella Health.
  • He is a serial biotech entrepreneur and investor, most notably having founded Intellia Therapeutics, Korro Bio and Liberate Bio.

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

Retrieved on: 
Thursday, January 5, 2023
Science, Other Science, Biotechnology, Pharmaceutical, General Health, Health, Infectious Diseases, Genetics, Sarepta, Partnership, GMP, Muscular dystrophy, Food, Duchenne muscular dystrophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DMD, AAV, BLA, Multimedia, Glossary, CDMO, Degenerative disease, Patient, NYSE, LGMD, FDA, SRPT, CTLT, Sarepta Therapeutics, Pharmaceutical industry, Catalent, Duchenne

The agreement also structures how Catalent may support multiple gene therapy candidates in Sarepta’s pipeline for limb-girdle muscular dystrophy (LGMD).

Key Points: 
  • The agreement also structures how Catalent may support multiple gene therapy candidates in Sarepta’s pipeline for limb-girdle muscular dystrophy (LGMD).
  • Under the terms of this expanded agreement, Catalent will be Sarepta’s primary commercial manufacturing partner for this therapy.
  • “Sarepta is working as quickly as possible to advance new genetic medicines to treat progressive neuromuscular diseases like Duchenne and LGMD.
  • Catalent is also the only contract development and manufacturing organization (CDMO) with a facility approved by the FDA for commercial manufacturing of an AAV gene therapy.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, November 30, 2022
Gene editing, Sarepta Therapeutics, Degenerative disease, Sarepta, RNA, SRPT, Employment, Therapy, Duchenne muscular dystrophy, Financial compensation, RSU, Muscular dystrophy, DMD, Pharmaceutical industry

The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received, in the aggregate, options to purchase 55,000 shares of Sarepta's common stock, and in the aggregate 28,500 restricted stock units (RSUs).
  • Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
  • We encourage investors and potential investors to consult our website regularly for important information about us.

Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

Retrieved on: 
Monday, November 28, 2022
COVID-19, Gene editing, Sarepta Therapeutics, Sarepta, Degenerative disease, Dystrophin, Food, RNA, Mutation, United States Patent and Trademark Office, Four-year junior college, SRPT, Safety, Partnership, Therapy, Shock, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Duchenne muscular dystrophy, Heart failure, Investor Protection and Securities Reform Act of 2010, Annual report, Priority review, File, Disease, Security (finance), Muscular dystrophy, DMD, Muscle weakness, Heart, Risk, Walking, Patent, Roche, EC, FDA, BLA, Medical device, Pharmaceutical industry, Duchenne

CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Biologics License Application (BLA) seeking accelerated approval of SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant individuals with Duchenne muscular dystrophy. SRP-9001 has been granted Priority Review by the FDA, with a regulatory action date of May 29, 2023.

Key Points: 
  • SRP-9001 has been granted Priority Review by the FDA, with a regulatory action date of May 29, 2023.
  • We are delighted to announce that the FDA has accepted Sareptas BLA for SRP-9001 for filing and priority review, said Doug Ingram, president and chief executive officer, Sarepta Therapeutics.
  • SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche.
  • For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta.

Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference

Retrieved on: 
Wednesday, November 23, 2022
Software, Gene editing, Sarepta Therapeutics, Degenerative disease, Sarepta, Event, Conference, RNA, SRPT, Therapy, Duchenne muscular dystrophy, Investor application, Muscular dystrophy, DMD

CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 2:15 p.m. E.T.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 2:15 p.m. E.T.
  • Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
  • Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.
  • We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com .